Abstract
Stroke is a leading cause of morbidity and mortality worldwide. It has been generally accepted that cerebrovascular remodeling during hypertension is one of the major contributors to the increased risk of stroke. Volume-regulated Cl- channel (VRCC) and calcium-activated Cl- channel (CaCC) are the two predominant types of Cl- channels in cerebral vascular smooth muscle cells (VSMC). Recent studies have demonstrated that ClC-3, a member of the voltage-gated ClC Cl- channel family, is the molecular candidate for VRCC in VSMC. And TMEM16A, a member of anoctamin family, is responsible for the native CaCC of VSMC in brain vessels. It has been shown that VRCC activity is enhanced but CaCC activity is decreased in cerebral VSMC, paralleling the severity of cerebrovascular remodeling induced by hypertension. In the present review, we will highlight the recent findings regarding the important roles of these two channels in VSMC proliferation, apoptosis, cell cycle regulation, vascular inflammation, reactive oxygen species production and cerebrovascular remodeling during the development of hypertension. In addition, the relationship between VRCC and clinical used agents for stroke prevention, such as statins, will be discussed. These findings suggest that Cl- channels may be potential new targets for the prevention of stroke.
Keywords: ClC-3, TMEM16A, cerebral vascular remodeling, stroke, proliferation, apoptosis, inflammation.
Current Vascular Pharmacology
Title:Chloride Channels − New Targets for the Prevention of Stroke
Volume: 13 Issue: 4
Author(s): Yan-Hua Du and Yong-Yuan Guan
Affiliation:
Keywords: ClC-3, TMEM16A, cerebral vascular remodeling, stroke, proliferation, apoptosis, inflammation.
Abstract: Stroke is a leading cause of morbidity and mortality worldwide. It has been generally accepted that cerebrovascular remodeling during hypertension is one of the major contributors to the increased risk of stroke. Volume-regulated Cl- channel (VRCC) and calcium-activated Cl- channel (CaCC) are the two predominant types of Cl- channels in cerebral vascular smooth muscle cells (VSMC). Recent studies have demonstrated that ClC-3, a member of the voltage-gated ClC Cl- channel family, is the molecular candidate for VRCC in VSMC. And TMEM16A, a member of anoctamin family, is responsible for the native CaCC of VSMC in brain vessels. It has been shown that VRCC activity is enhanced but CaCC activity is decreased in cerebral VSMC, paralleling the severity of cerebrovascular remodeling induced by hypertension. In the present review, we will highlight the recent findings regarding the important roles of these two channels in VSMC proliferation, apoptosis, cell cycle regulation, vascular inflammation, reactive oxygen species production and cerebrovascular remodeling during the development of hypertension. In addition, the relationship between VRCC and clinical used agents for stroke prevention, such as statins, will be discussed. These findings suggest that Cl- channels may be potential new targets for the prevention of stroke.
Export Options
About this article
Cite this article as:
Du Yan-Hua and Guan Yong-Yuan, Chloride Channels − New Targets for the Prevention of Stroke, Current Vascular Pharmacology 2015; 13 (4) . https://dx.doi.org/10.2174/1570161112666141014145040
DOI https://dx.doi.org/10.2174/1570161112666141014145040 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Homocysteine: A Risk Factor in Patietns with Cardiovascular Disorders in Pakistan
Current Bioactive Compounds Effective Agents Targeting the Mitochondria and Apoptosis to Protect the Heart
Current Pharmaceutical Design Anti-Inflammatory Approaches to Reduce Acute Cardiovascular Events: Not Only Benefits
Current Pharmaceutical Biotechnology Thrombophilia in Pregnancy: Maternal and Fetal Implications
Current Women`s Health Reviews Nocturnal Hypertension, Nondipping Phenomenon and Target Organ Damage in Obstructive Sleep Apnea Patients - The Bad and the Worse
Current Respiratory Medicine Reviews Efficacy of Cangrelor as Bridging Therapy Post PCI
Cardiovascular & Hematological Disorders-Drug Targets Spectral Features and In Vitro Antioxidant Study of Nanoscale Solid Dispersions of Different Sizes of Coenzyme Q<sub>10</sub> (CoQ<sub>10</sub>) Prepared by Heat Melt and High-pressure Homogenization Method
Current Nanoscience Anti-Diabetic Compounds and their Patent Information: An Update
Recent Patents on Inflammation & Allergy Drug Discovery Is Atorvastatin Superior to Other Statins? Analysis of the Clinical Trials with Atorvastatin Having Cardiovascular Endpoints
Reviews on Recent Clinical Trials Transgenerational Inheritance in the Offspring of Pregnant Women with Metabolic Syndrome
Current Pharmaceutical Biotechnology Regulation of Multidrug Resistance by Pro-Inflammatory Cytokines
Current Cancer Drug Targets Cardioprotective Peptides from Marine Sources
Current Protein & Peptide Science The Genetics of Small-Vessel Disease
Current Medicinal Chemistry The Role of AGEs and AGE Inhibitors in Diabetic Cardiovascular Disease
Current Drug Targets Cellular Senescence in Cardiovascular Diseases: Potential Age-Related Mechanisms and Implications for Treatment
Current Pharmaceutical Design Neuropeptides as Therapeutic Targets to Combat Stress-Associated Behavioral and Neuroendocrinological Effects
CNS & Neurological Disorders - Drug Targets The Association of Metabolic Syndrome and Psoriasis: A Systematic Review and Meta-Analysis of Observational Study
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeting Angiogenesis in Gastro-Intestinal Non Colorectal Cancers; A Review
Current Angiogenesis (Discontinued) Potential Approaches to Enhance the Effects of Estrogen on Senescent Blood Vessels and Postmenopausal Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Targets for the Treatment of Erectile Dysfunction: Is NO/cGMP Still the Answer?
Recent Patents on Cardiovascular Drug Discovery